Hidradenitis Suppurativa — SCE Dermatology MCQ

Instant feedback + full explanation. One question, done properly.

HardInflammatory DermatosesHidradenitis SuppurativaSCE Dermatology

A 55-year-old man has severe hidradenitis suppurativa. He has failed Clindamycin/Rifampicin and Adalimumab. What emerging biologic has shown efficacy in HS?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: E — Secukinumab

Secukinumab inhibits IL-17A and is a NICE-recommended option for active moderate-to-severe hidradenitis suppurativa in adults when conventional systemic treatment has been inadequate and adalimumab is unsuitable, ineffective or has lost effect. The other listed biologics target pathways used principally in allergic, eosinophilic, atopic or different inflammatory diseases and do not have the same established UK indication in this setting.

Reference: https://www.nice.org.uk/guidance/ta935